Andra AP fonden Buys Shares of 236,302 Astrazeneca Plc $AZN

Andra AP fonden bought a new position in Astrazeneca Plc (NYSE:AZN) during the 1st quarter, HoldingsChannel reports. The firm bought 236,302 shares of the company’s stock, valued at approximately $46,603,000. Astrazeneca accounts for 0.6% of Andra AP fonden’s investment portfolio, making the stock its 24th biggest holding.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. IHT Wealth Management LLC grew its holdings in shares of Astrazeneca by 0.3% in the 4th quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock valued at $3,076,000 after buying an additional 54 shares during the period. Visionary Wealth Advisors raised its stake in Astrazeneca by 1.5% during the 4th quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock worth $737,000 after buying an additional 60 shares during the period. Vista Investment Management lifted its holdings in Astrazeneca by 0.3% during the fourth quarter. Vista Investment Management now owns 21,215 shares of the company’s stock worth $3,723,000 after acquiring an additional 60 shares in the last quarter. Kestra Investment Management LLC lifted its holdings in Astrazeneca by 1.9% during the fourth quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock worth $595,000 after acquiring an additional 63 shares in the last quarter. Finally, Luken Investment Analytics LLC grew its stake in Astrazeneca by 4.3% in the fourth quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after acquiring an additional 64 shares during the period. 20.35% of the stock is owned by institutional investors.

Astrazeneca Stock Performance

AZN opened at $164.14 on Tuesday. The company has a market capitalization of $254.56 billion, a price-to-earnings ratio of 24.65, a P/E/G ratio of 1.38 and a beta of 0.24. The business’s 50-day moving average price is $181.80 and its two-hundred day moving average price is $188.30. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.06. The company had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. Equities analysts expect that Astrazeneca Plc will post 10.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on AZN shares. DZ Bank upgraded Astrazeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, April 29th. UBS Group reiterated a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. Barclays reiterated a “buy” rating on shares of Astrazeneca in a research report on Monday, June 1st. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Friday, June 26th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Astrazeneca has an average rating of “Moderate Buy” and a consensus price target of $211.00.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.